The 90% MIC of cefbuperazone (BMY 25182) was 32 ,Ig/ml for IacteroidesfragUis and Bacteroides spp., 128 ,ug/ml for Fusobacterium and Clostridium spp., 64 ,ug/ml for Eubacterium and Peptococcus spp., 8 jig/ml for Actinomyces spp., and 32 ,ig/mI for Peptostreptococcus spp. The level of activity of cefbuperazone was bigher edly resistant to cefbuperazone (MIC90, 128 ,ug/ml). In contrast, cefbuperazone was very effective against other species of the B. fragilis group such as Bacteroides thetaio-640
against B. fragiis and lower against anaerobic cocci than those of related cephalosporins, i.e., cefoxitin, cefoperazone, cefotaxime, ceftizoxime, and cefmenoxime. However, the activity of cefbuperazone was comparable to that of moxalactam against all groups tested. Size of inoculum and type of media used did not alter the MICs of cefbuperazone for B. fragilis. Cefbuperazone showed synergistic activity when combined with cefoxitin against resistant strains of B. fragilis.
Cefbuperazone (BMY 25182), chemically designated as 7 -[[2 -[[(4 -ethyl -2,3 -dioxo -1-piperazinyl)carbonyl]amino]-3-hy-droxy-1-oxobutyl]amino]-7-methoxy-3-[[(1-methyl-lHtetra-zol-5-yl)thio]methyl] -8 -oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, is a new semisynthetic cephamycin antimicrobial agent. It was found to be highly resistant to destruction by a variety of beta-lactamases (data from Bristol Laboratories, Syracuse, N.Y.). In this study, we evaluated the in vitro activity of this new cephamycin compound against clinical isolates of anaerobic bacteria. In addition, we compared its activity against anaerobic bacteria with those of related cephalosporins. We also tested the effects of medium composition, inoculum size, and the addition of cefoxitin on the MICs of cefbuperazone for Bacteroides fragilis.
The anaerobic bacteria used in this study were collected from Martin Luther King, Jr. General Hospital, Los Angeles. The identification of all bacteria was confirmed before the in vitro testing (4) . The antimicrobial agents were obtained from the following sources: cefbuperazone from Bristol Laboratories; cefoxitin from Merck & Co., Inc., Rahway, N.J.; moxalactam from Eli Lilly & Co., Indianapolis, Ind.; cefotaxime frorn Hoechst-Roussel Pharmaceuticals, Inc., Somerville, N.J.; cefoperazone from Pfizer Inc., New York, N.Y.; ceftizoxime from Smith Kline & French Laboratories, Philadelphia, Pa.; and cefmenoxime from Abbott Laboratories, North Chicago, Ill. Stock solutions of each antimicrobial agent were prepared according to the recommendations of the manufacturers.
MICs were determined by the agar dilution method, in which brain heart infusion agar containing defibrinated sheep blood, vitamin K, and hemin is used, as described previously (6) . B. fragilis ATCC 25285 and Clostridium perfringens ATCC 13124 were included in each experiment as control organisms. A set of control plates prepared with * Corresponding author. sterile water instead of antibiotics was inoculated and incubated aerobically and anaerobically. After being stamped with a Steers replicator (7), all plates were incubated in an anaerobic glove box (1) for 48 h at 37°C. The MIC was defined as the lowest concentration of an antibiotic that permitted no visible growth.
The effect of the inoculum on the MICs of cefbuperazone for 10 strains of B. fragilis was tested in brain heart infusion broth at 103, i01, and 108 CFU/ml by the broth dilution method (8) . The effects of the following four different media on the MICs of cefbuperazone for 32 clinical isolates of B. fragilis were tested by the agar dilution method (6): Wilkins-Chalgren agar (Difco Laboratories, Detroit, Mich.), thioglycolate-yeast extract agar (Difco), Mueller-Hinton agar (Difco), and brain heart infusion agar (BBk Microbiology Systems, Cockeysville, Md.). The effect of cefoxitin in combination with cefbuperazone against 10 multiply resistant strains of B. fragilis was determined by using the microtiter dilution checkerboard method (2, 3, 9) . Synergism was defined as a decrease of fourfold or greater in the MICs of both antibiotics, with reduction of at least 2 to 4 log1o CFU/ml.
A total of 326 clinical isolates of anaerobic bacteria was tested for in vitro activity of cefbuperazone in comparison with those of cefoxitin, moxalactam, cefotaxime, cefoperazone, ceftizoxime, and cefmenoxime. The results are expressed as the MIC range, MIC for 50% of the isolates (MIC50), MIC90, and the percentage of strains inhibited at achievable concentrations of each antimicrobial agent in serum ( Table 1 ). The MIC90 of cefbuperazone for B. fragilis was 32 ,ug/ml, which is comparable to that of moxalactam and is more effective than those of the other antibiotics mentioned above. It is important to note that six strains each of Bacteroides vulgatus and Bacteroides oralis were mark-NOTES jig/ml). Cefbuperazone was very effective against Actinomyces spp. (MIC90, 8 ,ug/ml). Cefbuperazone appears to be less effective against anaerobic cocci than the rest of the antibiotics used in this study. At achievable concentrations in serum, cefbuperazone was the most effective of all antibiotics tested against B. fragilis; it was found to inhibit 92% of all strains tested ( Table 1) . All of the test antibiotics inhibited more than 90% of the anaerobic cocci at levels achievable in serum, whereas cefbuperazone inhibited only 75% of Peptococcus spp. Increasing the inoculum of B. fragilis from 103 to 108 CFU/ml did not significantly alter the MICs of cefbuperazone. Different media had very little effect on the MICs of cefbuperazone for B. fragilis; the MIC90 of 92 strains tested was 32 p.g/ml in brain heart infusion agar, and it was 64 ,ug/ml in Wilkins-Chalgren agar, thioglycolate-yeast extract agar, and Mueller-Hinton agar. Cefbuperazone was synergistic with cefoxitin against 9 of the 10 strains of B. fragilis tested; one strain was indifferent. The indifferent isolate was resistant to both cefbuperazone MIC, >128 ,jg/ml) and cefoxitin (MIC, 64 ,ug/ml), and the organism remained resistant to a combination of the drugs. Indeed, the two drugs together produced a striking decrease of 6 to 8 logs CFU/ml in the final bacterial counts ( Table 2 ). Cefbuperazone, a new semisynthetic cephamycin, is stable to destruction by several beta-lactamases and was found to be effective against Enterobacteriaceae members (5) . Our study provides evidence that cefbuperazone is a relatively stable compound in different media and at different inoculum sizes in vitro and is effective against all major groups of anaerobic bacteria, including B. fragilis (MIC%0, 32 ,ug/ml).
We conclude that, with a single dose of 1-g intravenous infusion of cefbuperazone, peak levels of 114.2 ,ug/ml in serum (data from Bristol Laboratories) can be achieved, and such levels are well above the MIC90s for all anaerobes tested in this study except Fusobacterium and Clostridium spp. (MIC90 for each, 128 ,uglml) and for all aerobic bacteria (5) . For this reason, cefbuperazone appears to be a valuable therapeutic agent for treating mixed aerobic-anaerobic infections in humans.
